Ondansetron

Question 1

Generic Name:

Answer 1

Ondansetron

Question 2

Trade Name:

Answer 2

Zofran

Question 3

Supplied:

Answer 3

4mg/2mL

Question 4

Class:

Answer 4

Antiemetic agent

Question 5

Mechanism of Action:

Answer 5

Selectively blocks serotonin 5-HT3 receptors located in the CNS at the chemoreceptor trigger zone and in the peripheral nervous system on nerve-terminals of the vagus nerve

Question 6

Indications for use:

Answer 6

Nausea and vomiting

Question 7

Contraindications:

Answer 7

• Hypersensitivity
• Use with caution in patients with hepatic impairment
• Avoid use in patients with long QT syndrome

Question 8

Adverse Reactions:

Answer 8

CNS: Headache, malaise, fatigue, dizziness, fever, sedation, extrapyramidal syndrome

CV: Chest pain, arrhythmias

Resp: Hypoxia

GI/Hepatic: Diarrhea, constipation, abdominal pain, xerostomia, decreased appetite

Skin: Rash

Question 9

Incompatibilities/Drug Interactions:

Answer 9

Inducers or inhibitors of P450 drug metabolizing enzymes may alter the clearance of Ondansetron. No dosage adjustment is recommended.

Question 10

Adult Dosage:

Answer 10

4 – 8 mg IV slow push over 2 – 5 minutes 8 mg PO ODT or tablet

Question 11

Pediatric Dosage: (1 month to 12 years old):

Answer 11

• Greater than 40 kg- 4 mg IV slow push over 2 to 5
  minutes
• Less than 40 kg- 0.1 mg/kg IV slow push over 2 to 5 minutes
• 4-12 years old 4 mg PO ODT or ODT

Question 12

Routes of Administration:

Answer 12

IV, IM, PO

Question 13

Onset of Action:

Answer 13

Unknown but probably 10 to 30 minutes

Question 14

Peak Effects:

Answer 14

Unknown

Question 15

Duration of Action:

Answer 15

Half-life is approximately 4 hours. Exact duration unknown but appears to be prolonged compared to half-life.

Question 16

Arizona Drug Box Minimum Supply:

Answer 16

Optional: 4mg

Question 17

Special Notes:

Answer 17

•  Instructions for Use/Handling ZOFRAN ODT Orally Disintegrating Tablets: Do not attempt to push ZOFRAN ODT Tablets through the foil backing. With dry hands, PEEL BACK the foil backing of 1 blister and GENTLY remove the tablet. IMMEDIATELY place the ZOFRAN ODT Tablet on top of the tongue where it will dissolve in seconds, then swallow with saliva. Administration with liquid is not necessary.
•  Bottles: Store between 2°and 30°C (36  and 86°F). Protect from light. Dispense in tight, light-resistant container as defined in the USP.
•  Unit Dose Packs: Store between 2  and 30°C (36°and 86°F). Protect from light.
•  Store blisters in cartons.
•  ECG monitoring for patients with electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia), congestive heart failure, bradyarrhythmias, or for patients taking other medications that can lead to QT prolongation, is recommended.